Allergy and asthma proceedings :
-
Allergy Asthma Proc · Nov 2010
Randomized Controlled Trial Multicenter StudyNebulized dehydroepiandrosterone-3-sulfate improves asthma control in the moderate-to-severe asthma results of a 6-week, randomized, double-blind, placebo-controlled study.
Inhaled dehydroepiandrosterone-3-sulfate (DHEAS), but not dehydroepiandrosterone (DHEA), possesses anti-inflammatory activity in in vitro assays and in models of allergen and lipopolysaccharide challenges. We postulated whether an inhaled suspension of DHEAS delivered via nebulizer would improve asthma control in moderate-to-severe asthma patients. We also characterized the safety profile of an inhaled suspension of DHEAS. ⋯ AUSTRALIAN NEW ZEALAND CLINICAL TRIALS REGISTRY ANZCTR. ORG. AU IDENTIFIER: 012607000192482.